Status:
TERMINATED
VELCADE,Rituximab,Cyclophosphamide and Decadron
Lead Sponsor:
Oncology Specialists, S.C.
Collaborating Sponsors:
Millennium Pharmaceuticals, Inc.
Conditions:
Lymphoma, Non-Hodgkin
Lymphoma, B-Cell
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
Overall response rate and Time to disease progression using this regimen in patients with low-grade B-Cell Non-Hodgkin's Lymphoma.
Detailed Description
This is a phase II open label study that is looking at the VRCD combination regimen in patients with previously untreated low-grade Non-Hodgkin's Lymphoma. Treatment will start by combining oral dexam...
Eligibility Criteria
Inclusion
- Small Lymphocytic Lymphoma
- Follicular Cell Lymphoma (grades I and II)
- Mantle Cell Lymphoma patients that are not considered eligible for high-dose therapy and stem cell transplant
- Lymphoplasmacytic lymphoma including Waldenstrom's Macroglobulinemia
- Marginal Zone Lymphoma
- MALT Lymphoma that has ONLY failed antibiotic therapy or involved field radiation.
- Adequate bone marrow function, renal function, and hepatic function as outlined in details below.
- ECOG performance status of 0, 1, or 2
- Able to read, understand, and sign an IRB approved informed consent
Exclusion
- Known HIV positive status
- Known CNS involvement
- Prior therapy for lymphoma EXCLUDING antibiotic treatment for MALT-Type NHL.
Key Trial Info
Start Date :
August 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00413959
Start Date
August 1 2006
End Date
January 1 2011
Last Update
September 19 2018
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Onocology Specialists, S.C
Niles, Illinois, United States, 60714
2
Oncology Specialists, S.C
Park Ridge, Illinois, United States, 60068